Three cases are described, 2 of Hodgkin's disease and a further case of bronchial carcinoma, where high dosage ascorbic acid treatment appeared to be associated with the development of potentially dangerous symptoms. It is suggested that mega ascorbic acid therapy should be given with caution in malignant disease, with a slow build-up over several days to high levels of dosage.
Get full access to this article
View all access options for this article.
References
1.
CameronE. (1966). Hyaluronidindase and Cancer. Oxford: Pergamon.
2.
CameronE. (1978). Personal communication.
3.
CameronE.CampbellA. (1974). The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chemical Biological Interactions, 9, 285.
4.
CameronE.PaulingL. (1974). The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chemical Biological Interaction, 9, 273.
5.
CameronE.PaulingL. (1976). Supplemental ascorbate in the supportive treatment of cancer. Prolongation of survival times in Terminal human cancer. Proceedings of the National Academy of Sciences of the United States of America, 73, No. 10.
6.
CameronE.CampbellA.JackT. (1975). The orthomolecular treatment of cancer. III. Reticulum Cell Sarcoma: Double complete regression induced by high-dose Ascorbic acid therapy. Chemica Biological Interactions, 11, 387.
7.
MigliozziJ. A. (1977). Effect of ascorbic acid on tumour growth. British Journal of Cancer, 35, 448.
8.
RussellW. O. (1952). Studies on methylcholantrene. Induction of Tumours in scorbutic guinea pigs. Cancer Research, 12, 216.
9.
StoneI. (1972). The Healing Factor. Vitamin C against disease, p90. New York: Grosset and Dunlop.
